Valuation : GENFIT

Market Cap 65Cr 76Cr 62Cr 56Cr 104.87Cr 7.22TCr 105.4Cr 732.46Cr 281.66Cr 3.67TCr 283.9Cr 277.67Cr 12TCr P/E 2026 *
33.5x
P/E 2027 * 74.3x
Enterprise Value 60Cr 70Cr 57Cr 52Cr 97Cr 6.66TCr 97Cr 674.98Cr 259.56Cr 3.39TCr 261.62Cr 255.88Cr 11TCr EV / Sales 2026 *
5.98x
EV / Sales 2027 * 4.67x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-5.28%
1 week-5.69%
Current month-7.71%
1 month+2.38%
3 months+44.84%
6 months+44.76%
Current year+153.33%
1 week 11.8
Extreme 11.8
14.24
1 month 11.8
Extreme 11.8
14.8
Current year 5.06
Extreme 5.055
15.4
1 year 3.58
Extreme 3.578
15.4
3 years 3.3
Extreme 3.305
15.4
5 years 2.96
Extreme 2.964
15.4
10 years 2.96
Extreme 2.964
21.74
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-5.28%-5.69% - - 80Cr
-0.71%-6.35%-4.87%+9.03% 4.61TCr
+0.21%-2.98%+340.68%+519.93% 4.36TCr
+1.74%-2.24%+37.28%+21.57% 4.24TCr
+1.38%-3.28%+3.23%+65.60% 3.89TCr
-1.44%-5.26%+8.78%+36.85% 3.22TCr
+0.87%-2.60% - - 1.72TCr
+0.75%-0.64%+18.07%+110.32% 1.63TCr
-0.31%-2.78%+10.47%+30.49% 1.43TCr
+1.93%-3.55%+74.20%+39.37% 1.3TCr
Average -0.09%-4.23%+60.98%+104.14% 2.93TCr
Weighted average by Cap. +0.38%-4.51%+73.05%+123.51%

Financials

2026 *2027 *
Net sales 10Cr 12Cr 9.5Cr 8.61Cr 16Cr 1.11TCr 16Cr 112.78Cr 43Cr 565.73Cr 44Cr 43Cr 1.79TCr 13Cr 15Cr 12Cr 11Cr 20Cr 1.39TCr 20Cr 141.04Cr 54Cr 707.48Cr 55Cr 53Cr 2.24TCr
Net income 2.29Cr 2.66Cr 2.17Cr 1.96Cr 3.68Cr 253.67Cr 3.7Cr 26Cr 9.89Cr 129.06Cr 9.97Cr 9.75Cr 407.81Cr 68L 78.92L 64.39L 58.36L 1.09Cr 75Cr 1.1Cr 7.65Cr 2.94Cr 38Cr 2.96Cr 2.9Cr 121.21Cr
Net Debt -5.11Cr -5.93Cr -4.84Cr -4.39Cr -8.23Cr -566.68Cr -8.27Cr -57Cr -22Cr -288.3Cr -22Cr -22Cr -911Cr -6.59Cr -7.64Cr -6.24Cr -5.65Cr -11Cr -730.25Cr -11Cr -74Cr -28Cr -371.52Cr -29Cr -28Cr -1.17TCr
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
11/26/11 €12.92 -5.28% 12,974
10/26/10 €13.64 +12.17% 11,159
09/26/09 €12.16 -6.61% 14,147
08/26/08 €13.02 -3.98% 10,311
07/26/07 €13.56 -1.02% 3,100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.02EUR
Average target price
17.15EUR
Spread / Average Target
+31.72%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!